Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FOSAMAX/PREMARIN COMBO DATA FOR OSTEOPOROSIS TREATMENT WILL BE AVAILABLE BY YEAR-END; MERCK SAYS IT WILL NOT TRY TO "SWITCH" PREMARIN USERS TO FOSAMAX

Executive Summary

A study of Merck's Fosamax in combination with Wyeth Ayerst's conjugated estrogens product Premarin will be completed in August or September, Merck told the financial community on Feb. 20 following a meeting of the Endocrinologic & Metabolic Drugs Advisory Committee.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel